Liver cancer is a common malignant tumor, and 55% of hepatocellular carcinoma worldwide occurs in China. According to the 2005 national census, it is estimated that there were more than 370,000 new cases of liver cancer and more than 330,000 deaths in China between 2004 and 2005. Due to the insidious onset of the disease, most patients with hepatocellular carcinoma are already in the middle and late stages when diagnosed, and often lose the opportunity for radical surgery; only 10-15% of the first diagnosed patients can be radically resected, and the recurrence rate is as high as 50-80% within 5 years after surgery. The efficacy of advanced stage patients is very poor due to intractable conditions such as liver insufficiency and distant metastasis, and the 5-year survival rate is less than 5%. Chemotherapy has no significant survival benefit for patients with advanced hepatocellular carcinoma. The current treatment means of liver cancer mainly include surgical resection, local ablation, intervention, molecular targeted therapy drugs and other means. 1.Liver transplantation or surgical resection: mainly used for the treatment of ultra early stage liver cancer, which can achieve better curative effect. For other stages of liver cancer, the efficacy of surgery is comparable to that of ablation or intervention, but it is more damaging to patients, so for early, middle and late stage liver cancer, non-surgical treatment is generally recommended. Local ablation or intervention can also be applied to control tumor growth while waiting for liver transplantation. 2.Local ablation: It is mainly used for the treatment of early and mid-stage liver cancer. It can also be used for ultra-early stage liver cancer that is not suitable for surgery or patients are unwilling to undergo surgery, such as tumor location (e.g. near large blood vessels), and can also be used to reduce the load of advanced liver cancer. Local ablation can be performed by percutaneously puncturing the ablation needle to the appropriate location of the tumor to achieve necrosis of the tumor through different physicochemical means, which is less harmful to the body. At present, it is mainly divided into thermal ablation (radiofrequency, microwave), cold ablation (argon helium knife) and anhydrous alcohol injection, which are purely physical means without the toxic side effects of chemotherapy and radiotherapy. Thermal ablation (radiofrequency, microwave) mainly achieves the purpose of killing tumor through ultra-high temperature. Cold ablation (Ar-He knife) mainly causes necrosis and disintegration of tumor cells through ultra-low temperature. The advantage of cold ablation over thermal ablation and other treatments is that the collapsed tumor cells will release a series of tumor antigens and factors, which will stimulate the body to produce immune response against tumor and can effectively prevent the recurrence and new tumor development. Therefore, argon helium knife ablation has the advantage of inducing tumor immunity that other liver cancer treatment methods do not have, and is also the main liver cancer treatment method promoted by our liver cancer treatment center. Anhydrous alcohol injection: Anhydrous alcohol is injected into the tumor to kill the tumor, which is usually used in conjunction with hot and cold ablation. 3.Interventional therapy: In fact, in a broad sense, local ablation is also a kind of interventional therapy, but the current interventional therapy usually refers to hepatic artery chemoembolization therapy (TACE), which is mainly used for the treatment of middle and late stage liver cancer. Compared with local ablation, TACE gradually causes ischemia and necrosis of tumor, and it usually takes 1 month to check the treatment effect by MR, while local ablation kills the tumor at that time, and the treatment effect can be understood by re-examination of CT or MR after 3 days. TACE has better therapeutic effect for tumors with rich blood supply, but it is basically ineffective for tumors without blood supply. 4.Molecular targeted therapy drugs: Molecular targeted therapy drugs are anti-tumor drugs used in recent years, and only one drug, Doxorubicin (generic name: sorafenib mesylate), has been approved by FDA and SFDA of China for the treatment of distant metastases or liver cancer that cannot be surgically resected, mainly for the treatment of intermediate and advanced liver cancer, which can effectively prolong the median survival. 5. Besides the above therapies which are widely recognized by international academic circles, there are some other therapies: Chinese medicine: Chinese medicine, as a unique therapeutic means in China, has achieved good efficacy in many liver cancer patients, but: (1) the formulae of different doctors in different hospitals vary greatly and fail to form a unified standard, and the efficacy is also mixed; (2) the international academic circles do not have a deep understanding of Chinese medicine and it is not accepted by the world. (3) Most of the patients receiving traditional Chinese medicine treatment are advanced or even end-stage liver cancer patients for whom other treatments are ineffective, so their prognosis is poor and their efficacy is naturally inferior to that of early and mid-stage patients receiving other treatments. Radiotherapy: liver cancer is usually not sensitive to radiotherapy, but some new technologies such as Hepatome and Radiofrequency Knife have also shown better efficacy. Radiotherapy is usually used for the treatment of middle and advanced stage liver cancer. Cellular biotherapy: mainly refers to CIK etc., which is mainly used for the treatment of advanced liver cancer.